文献速递神经肿瘤脑血管病外科

颈静脉副神经节瘤接受伽玛刀放射外科治疗的长期结局:单中心经验

Long-Term Outcomes of Jugular Paragangliomas Undergoing Gamma Knife Radiosurgery: A Single Center Experience.
PubMed 文献 · Neurosurgery · 2025-01-29

该单中心回顾性研究分析了40例颈静脉副神经节瘤患者接受伽玛刀放射外科治疗的长期结局,中位随访69.7个月,肿瘤控制率95%,症状控制与功能保留率97.5%,原发与辅助伽玛刀治疗后15年无进展生存率分别为100%与83.3%。作者认为伽玛刀是安全有效的微创治疗,可考虑作为首选管理及术后残余或复发肿瘤的早期辅助策略。

要点

  • 40例颈静脉副神经节瘤接受伽玛刀,中位边缘剂量13.5 Gy,中位随访69.7个月。
  • 肿瘤控制率95%(退缩23例、稳定15例),症状控制与功能保留率97.5%。
  • 原发伽玛刀5、10、15年无进展生存率均为100%,辅助伽玛刀为91.7%、83.3%、83.3%(P=0.101)。

核心结论

  • 伽玛刀放射外科作为微创管理,被证明是颈静脉副神经节瘤安全有效的治疗。
  • 作者认为伽玛刀应被考虑作为最佳的首选管理以及初始切除后残余或复发肿瘤的早期辅助策略。

研究设计与样本

  • 回顾性单中心研究,复习3.5十年间17800例患者的伽玛刀放射外科数据库。
  • 纳入40例患者(中位年龄56岁,范围18-88岁,女性24例)共40个颈静脉副神经节瘤,其中原发伽玛刀28例、辅助伽玛刀12例。
  • 中位边缘剂量13.5 Gy(范围12-18 Gy),处方于50%等剂量线。

主要发现

  • 辅助伽玛刀组中分期体积放射外科(2次)更多(n=1 vs n=3,P=0.035),与更大肿瘤体积[3.5 cc(1.1-26.7)vs 10.2 cc(3.3-45.9),P=0.038]及V12Gy增加(P=0.031)相关。
  • 伽玛刀前更好的House-Brackmann分级(P=0.008)与治疗后更好的面神经功能相关,更好的Gardner-Robertson听力分级(P<0.001)与治疗后耳蜗神经功能不变相关。
  • 中位随访69.7个月(范围6.0-339.3个月)期间,39例(97.5%)实现症状控制与功能保留。
  • 38例(95%)实现肿瘤控制(退缩23例、稳定15例)。
  • 原发伽玛刀后5、10、15年无进展生存率均为100%,辅助伽玛刀后分别为91.7%、83.3%、83.3%(P=0.101)。

临床怎么用

  • 作者认为伽玛刀应被考虑作为颈静脉副神经节瘤的最佳首选管理。
  • 作者认为伽玛刀应被考虑作为初始切除后残余或复发肿瘤的早期辅助策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Jugular paragangliomas (JPG) pose a surgical challenge because of their vascularity and complex location. Stereotactic radiosurgery (SRS) offers a minimally invasive management for patients with JPG. Our aim was to evaluate outcomes of Gamma Knife radiosurgery (GKRS) for the treatment of JPG over the long term. METHODS: We reviewed our 3.5-decade 17 800 patients' GKRS database. Clinical behavior, treatment parameters, tumor control, complications, and functional status were assessed. RESULTS: Forty patients (median = 56 years [range, 18-88], women = 24) with 40 JPG were included. There were 28 primary and 12 adjuvant GKRS. The median margin dose was 13.5 Gy (range, 12-18) delivered at 50% isodose line. Among patients with adjuvant GKRS, there were more staged-volume SRS (2 sessions) (n = 1 vs n = 3, P = .035) associated with larger tumor volume [3.5 cc (1.1-26.7) vs 10.2 cc (3.3-45.9), ( P = .038) and increased V12Gy ( P = .031). Better House-Brackmann grade ( P = .008) and Gardner-Robertson hearing class ( P < .001) before GKRS correlated with better facial nerve function and unchanged cochlear nerve function after treatment, respectively. During an overall median follow-up of 69.7 months (range, 6.0-339.3 months), symptom control and preserved functionality were achieved in 39 patients (97.5%). Tumor control was obtained in 38 patients (95%) (regression = 23, stable = 15) after SRS. The 5-, 10-, and 15-year progression-free survival rates were all 100% after primary GKRS and 91.7%, 83.3%, and 83.3% for adjuvant GKRS ( P = .101). Larger (≥10 cc) tumor volumes (HR: 1.35 [95% CI: 1.11-1.70], P = .013) and mFisch Di2 (HR: 1.40 [95% CI: 1.18-1.64], P = .016) were associated with worse progression-free survival. One patient required a second GKRS after asymptomatic progression with no further growth. One patient with 2 failed surgical resections died 8 months after adjuvant GKRS related to tumor progression and hydrocephalus. CONCLUSION: As a minimally invasive management, GKRS proved to be a safe and effective treatment of JPG. GKRS should be considered both as an optimal primary management and as an early adjuvant strategy for residual or recurrent tumors after initial resection.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Daza-Ovalle A, Bin-Alamer O, Wei Z, et al. Long-Term Outcomes of Jugular Paragangliomas Undergoing Gamma Knife Radiosurgery: A Single Center Experience. Neurosurgery. 2025. PMID: 39878475. doi:10.1227/neu.0000000000003357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。